REFERENCES
3. Anderson S, Bankier AT, Barrell BG, et al. Sequence and organization of the human mitochondrial genome. Nature 1981;290:457-65.
4. Barshad G, Marom S, Cohen T, Mishmar D. Mitochondrial DNA transcription and its regulation: an evolutionary perspective. Trends Genet 2018;34:682-92.
5. Sbisà E, Tanzariello F, Reyes A, Pesole G, Saccone C. Mammalian mitochondrial D-loop region structural analysis: identification of new conserved sequences and their functional and evolutionary implications. Gene 1997;205:125-40.
6. Berardo A, Musumeci O, Toscano A. Cardiological manifestations of mitochondrial respiratory chain disorders. Acta Myol 2011;30:9-15.
8. Fukui H, Moraes CT. Mechanisms of formation and accumulation of mitochondrial DNA deletions in aging neurons. Hum Mol Genet 2009;18:1028-36.
9. Nesbitt V, Pitceathly RDS, Turnbull DM, et al. The UK MRC mitochondrial disease patient cohort study: clinical phenotypes associated with the m.3243A>G mutation-implications for diagnosis and management. J Neurol Neurosurg Psychiatry 2013;84:936-8.
10. Lake NJ, Compton AG, Rahman S, Thorburn DR. Leigh syndrome: one disorder, more than 75 monogenic causes. Ann Neurol 2016;79:190-203.
11. Orekhov AN, Gerasimova EV, Sukhorukov VN, Poznyak AV, Nikiforov NG. Do mitochondrial DNA mutations play a key role in the chronification of sterile inflammation? Curr Pharm Des 2021;27:276-92.
12. Sobenin IA, Sazonova MA, Postnov AY, Salonen JT, Bobryshev YV, Orekhov AN. Association of mitochondrial genetic variation with carotid atherosclerosis. PLoS One 2013;8:e68070.
13. Gencer S, Evans BR, van der Vorst EPC, Döring Y, Weber C. Inflammatory chemokines in atherosclerosis. Cells 2021;10:226.
15. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 2014;94:909-50.
16. van der Bliek AM, Sedensky MM, Morgan PG. Cell biology of the mitochondrion. Genetics 2017;207:843-71.
17. Brand MD, Orr AL, Perevoshchikova IV, Quinlan CL. The role of mitochondrial function and cellular bioenergetics in ageing and disease. Br J Dermatol 2013;169:1-8.
18. Lin DS, Huang YW, Ho CS, et al. Oxidative insults and mitochondrial DNA mutation promote enhanced autophagy and mitophagy compromising cell viability in pluripotent cell model of mitochondrial disease. Cells 2019;8:65.
19. Salnikova D, Orekhova V, Grechko A, et al. Mitochondrial dysfunction in vascular wall cells and its role in atherosclerosis. Int J Mol Sci 2021;22:8990.
20. Hayat MA. Autophagy: cancer, other pathologies, inflammation, immunity, infection, and aging. 2015. Available from: https://linkinghub.elsevier.com/retrieve/pii/C2013018837X [Last accessed on 5 Dec 2023].
21. Soucy-Faulkner A, Mukawera E, Fink K, et al. Requirement of NOX2 and reactive oxygen species for efficient RIG-I-mediated antiviral response through regulation of MAVS expression. PLoS Pathog 2010;6:e1000930.
22. Marchio P, Guerra-Ojeda S, Vila JM, Aldasoro M, Victor VM, Mauricio MD. Targeting early atherosclerosis: a focus on oxidative stress and inflammation. Oxid Med Cell Longev 2019;2019:8563845.
23. Sentman ML, Brännström T, Westerlund S, et al. Extracellular superoxide dismutase deficiency and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2001;21:1477-82.
24. Schrepfer E, Scorrano L. Mitofusins, from mitochondria to metabolism. Molecular Cell 2016;61:683-94.
25. Twig G, Elorza A, Molina AJA, et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J 2008;27:433-46.
26. Westermann B. Bioenergetic role of mitochondrial fusion and fission. Biochim Biophys Acta 2012;1817:1833-8.
27. Palikaras K, Lionaki E, Tavernarakis N. Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. Nat Cell Biol 2018;20:1013-22.
28. Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP, Youle RJ. Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J Cell Biol 2010;191:933-42.
30. Kane LA, Lazarou M, Fogel AI, et al. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol 2014;205:143-53.
31. Villa E, Marchetti S, Ricci JE. No Parkin zone: mitophagy without parkin. Trends Cell Biol 2018;28:882-95.
32. Liu L, Sakakibara K, Chen Q, Okamoto K. Receptor-mediated mitophagy in yeast and mammalian systems. Cell Res 2014;24:787-95.
33. Sentelle RD, Senkal CE, Jiang W, et al. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat Chem Biol 2012;8:831-8.
34. Ohtake F, Tsuchiya H, Saeki Y, Tanaka K. K63 ubiquitylation triggers proteasomal degradation by seeding branched ubiquitin chains. Proc Natl Acad Sci USA 2018;115:E1401-8.
35. Hariharan N, Maejima Y, Nakae J, Paik J, Depinho RA, Sadoshima J. Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. Circ Res 2010;107:1470-82.
36. Kim J, Guan KL. Regulation of the autophagy initiating kinase ULK1 by nutrients: roles of mTORC1 and AMPK. Cell Cycle 2011;10:1337-8.
37. Nwadike C, Williamson LE, Gallagher LE, Guan JL, Chan EYW. AMPK inhibits ULK1-dependent autophagosome formation and lysosomal acidification via distinct mechanisms. Mol Cell Biol 2018;38:e00023-18.
38. Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. BBA Mol Cell Res 2011;1813:1269-78.
39. Gleyzer N, Vercauteren K, Scarpulla RC. Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators. Mol Cell Biol 2005;25:1354-66.
40. Kong X, Wang R, Xue Y, et al. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One 2010;5:e11707.
42. Quan Y, Xin Y, Tian G, Zhou J, Liu X. Mitochondrial ROS-modulated mtDNA: a potential target for cardiac aging. Oxid Med Cell Longev 2020;2020:9423593.
43. Nakahira K, Haspel JA, Rathinam VAK, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011;12:222-30.
44. Wei MC, Zong WX, Cheng EHY, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727-30.
45. Chen L, Peng J, Wang Y, et al. Fenofibrate-induced mitochondrial dysfunction and metabolic reprogramming reversal: the anti-tumor effects in gastric carcinoma cells mediated by the PPAR pathway. Am J Transl Res 2020;12:428-46.
46. Oslowski CM, Hara T, O’sullivan-murphy B, et al. Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome. Cell Metab 2012;16:265-73.
47. Sakurai A, Nishimoto M, Himeno S, et al. Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2. J Cell Physiol 2005;203:529-37.
48. Swanson KV, Deng M, Ting JPY. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol 2019;19:477-89.
49. Wu N, Zheng B, Shaywitz A, et al. AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell 2013;49:1167-75.
50. Han X, Xu T, Fang Q, et al. Quercetin hinders microglial activation to alleviate neurotoxicity via the interplay between NLRP3 inflammasome and mitophagy. Redox Biol 2021;44:102010.
51. Holt IJ, Cooper JM, Morgan-Hughes JA, Harding AE. Deletions of muscle mitochondrial DNA. Lancet 1988;1:1462.
52. Ng YS, Bindoff LA, Gorman GS, et al. Mitochondrial disease in adults: recent advances and future promise. Lancet Neurol 2021;20:573-84.
54. Mancuso M, Petrozzi L, Filosto M, et al. MERRF syndrome without ragged-red fibers: the need for molecular diagnosis. Biochem Biophys Res Commun 2007;354:1058-60.
55. Zeviani M, Moraes CT, DiMauro S, et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1988;38:1339-46.
56. Wallace DC. Mitochondrial defects in neurodegenerative disease. Ment Retard Dev Disabil Res Rev 2001;7:158-66.
57. Rossignol R, Faustin B, Rocher C, Malgat M, Mazat JP, Letellier T. Mitochondrial threshold effects. Biochem J 2003;370:751-62.
58. Schmiedel J, Jackson S, Schäfer J, Reichmann H. Mitochondrial cytopathies. J Neurol 2003;250:267-77.
59. Johns DR, Neufeld MJ, Park RD. An ND-6 mitochondrial DNA mutation associated with Leber hereditary optic neuropathy. Biochem Biophys Res Commun 1992;187:1551-7.
60. Marie SKN, Oba-shinjo SM, Marques-dias MJ, Rosemberg S, Kok F, Reed UC. The prevalence of mitochondrial DNA mutations in Leigh syndrome in a Brazilian series. Med Express 2014;1:239-42. Available from: https://www.scielo.br/j/medical/a/zRN3Vnp8Vj6DDKQBnSHyZkR/?lang=en [Last accessed on 7 Dec 2023]
61. de Vries DD, van Engelen BGM, Gabreëls FJM, Ruitenbeek W, van Oost BA. A second missense mutation in the mitochondrial ATPase 6 gene in Leigh’s syndrome. Ann Neurol 1993;34:410-2.
62. Leng Y, Liu Y, Fang X, et al. The mitochondrial DNA 10197 G >A mutation causes MELAS/leigh overlap syndrome presenting with acute auditory agnosia. Mitochondrial DNA 2015;26:208-12.
63. Shanske S, Coku J, Lu J, et al. The G13513A mutation in the ND5 gene of mitochondrial DNA as a common cause of MELAS or Leigh syndrome: evidence from 12 cases. Arch Neurol 2008;65:368-72.
64. Lorenzoni PJ, Scola RH, Kay CSK, Silvado CES, Werneck LC. When should MERRF (myoclonus epilepsy associated with ragged-red fibers) be the diagnosis? Arq Neuro-Psiquiatr 2014;72:803-11.
65. Wang YX, Le WD. Progress in diagnosing mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Chin Med J 2015;128:1820-5.
66. Gil Borlado MC, Moreno Lastres D, Gonzalez Hoyuela M, et al. Impact of the mitochondrial genetic background in complex III deficiency. PLoS One 2010;5:e12801.
67. Yan N, Cai S, Guo B, et al. A novel mitochondrial tRNA(Val) T1658C mutation identified in a CPEO family. Mol Vis 2010;16:1736-42.
68. Elson JL, Swalwell H, Blakely EL, McFarland R, Taylor RW, Turnbull DM. Pathogenic mitochondrial tRNA mutations-which mutations are inherited and why? Hum Mutat 2009;30:E984-92.
69. Zapico SC, Ubelaker DH. mtDNA mutations and their role in aging, diseases and forensic sciences. Aging Dis 2013;4:364-80.
70. Maassen JA, van den Ouweland JM, t Hart LM, Lemkes HH. Maternally inherited diabetes and deafness: a diabetic subtype associated with a mutation in mitochondrial DNA. Horm Metab Res 1997;29:50-5.
71. Chen FL, Liu Y, Song XY, et al. A novel mitochondrial DNA missense mutation at G3421A in a family with maternally inherited diabetes and deafness. Mutat Res 2006;602:26-33.
72. Zhelankin AV, Sazonova MA. [Association of the mutations in the human mitochondrial genome with chronic non-inflammatory diseases: type 2 diabetes, hypertension and different types of cardiomyopathy]. Patol Fiziol Eksp Ter 2012;3:123-8.
73. Wortmann SB, Champion MP, van den Heuvel L, et al. Mitochondrial DNA m.3242G>A mutation, an under diagnosed cause of hypertrophic cardiomyopathy and renal tubular dysfunction? Eur J Med Genet 2012;55:552-6.
74. Ma L, Wang H, Chen J, et al. Mitochondrial gene variation in type 2 diabetes mellitus: detection of a novel mutation associated with maternally inherited diabetes in a Chinese family. Chin Med J 2000;113:111-6.
75. Schaefer AM, Walker M, Turnbull DM, Taylor RW. Endocrine disorders in mitochondrial disease. Mol Cell Endocrinol 2013;379:2-11.
76. Dabravolski SA, Orekhova VA, Baig MS, et al. The role of mitochondrial mutations and chronic inflammation in diabetes. Int J Mol Sci 2021;22:6733.
77. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006;38:515-7.
78. Kaukonen J, Juselius JK, Tiranti V, et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 2000;289:782-5.
79. Spelbrink JN, Li FY, Tiranti V, et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet 2001;28:223-31.
80. Van Goethem G, Dermaut B, Löfgren A, Martin JJ, Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001;28:211-2.
81. Petros JA, Baumann AK, Ruiz-Pesini E, et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 2005;102:719-24.
82. Dabravolski SA, Bezsonov EE, Orekhov AN. The role of mitochondria dysfunction and hepatic senescence in NAFLD development and progression. Biomed Pharmacother 2021;142:112041.
83. Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Orekhov AN. Mitochondrial lipid homeostasis at the crossroads of liver and heart diseases. Int J Mol Sci 2021;22:6949.
84. Ding Y, Leng J, Fan F, Xia B, Xu P. The role of mitochondrial DNA mutations in hearing loss. Biochem Genet 2013;51:588-602.
85. Malekmohammad K, Bezsonov EE, Rafieian-Kopaei M. Role of lipid accumulation and inflammation in atherosclerosis: focus on molecular and cellular mechanisms. Front Cardiovasc Med 2021;8:707529.
86. Bezsonov EE, Sobenin IA, Orekhov AN. Immunopathology of atherosclerosis and related diseases: focus on molecular biology. Int J Mol Sci 2021;22:4080.
87. Mushenkova NV, Bezsonov EE, Orekhova VA, Popkova TV, Starodubova AV, Orekhov AN. Recognition of oxidized lipids by macrophages and its role in atherosclerosis development. Biomedicines 2021;9:915.
88. Mezentsev A, Bezsonov E, Kashirskikh D, Baig MS, Eid AH, Orekhov A. Proatherogenic sialidases and desialylated lipoproteins: 35 years of research and current state from bench to bedside. Biomedicines 2021;9:600.
89. Bezsonov E, Borisov E, Vinokurov A, et al. Effects of native and modified low-density lipoproteins on mitophagy. Atherosclerosis 2023;375:98-100.
90. Tian F, Li J, Liu XW, Tong TJ, Zhang ZY. Age-dependent accumulation of mitochondrial DNA deletions in the aortic root of atherosclerosis-prone apolipoprotein E-knockout mice. Arch Gerontol Geriatr 2016;63:72-7.
91. Umbria M, Ramos A, Aluja MP, Santos C. The role of control region mitochondrial DNA mutations in cardiovascular disease: stroke and myocardial infarction. Sci Rep 2020;10:2766.
92. Mitrofanov KY, Zhelankin AV, Shiganova GM, et al. Analysis of mitochondrial DNA heteroplasmic mutations A1555G, C3256T, T3336C, С5178А, G12315A, G13513A, G14459A, G14846А and G15059A in CHD patients with the history of myocardial infarction. Exp Mol Pathol 2016;100:87-91.
93. Sawabe M, Tanaka M, Chida K, et al. Mitochondrial haplogroups A and M7a confer a genetic risk for coronary atherosclerosis in the Japanese elderly: an autopsy study of 1,536 patients. J Atheroscler Thromb 2011;18:166-75.
94. Kirichenko TV, Sobenin IA, Khasanova ZB, et al. Data on association of mitochondrial heteroplasmy and cardiovascular risk factors: comparison of samples from Russian and Mexican populations. Data Brief 2018;18:16-21.
95. Sazonova MA, Sinyov VV, Barinova VA, et al. Mosaicism of mitochondrial genetic variation in atherosclerotic lesions of the human aorta. Biomed Res Int 2015;2015:825468.
96. Ashar FN, Zhang Y, Longchamps RJ, et al. Association of mitochondrial DNA copy number with cardiovascular disease. JAMA Cardiol 2017;2:1247-55.
97. Liu LP, Cheng K, Ning MA, et al. Association between peripheral blood cells mitochondrial DNA content and severity of coronary heart disease. Atherosclerosis 2017;261:105-10.
98. Hu H, Lin Y, Xu X, Lin S, Chen X, Wang S. The alterations of mitochondrial DNA in coronary heart disease. Exp Mol Pathol 2020;114:104412.
99. Willcox JAL, Geiger JT, Morton SU, et al. Neither cardiac mitochondrial DNA variation nor copy number contribute to congenital heart disease risk. Am J Hum Genet 2022;109:961-6.
100. Poznyak AV, Bezsonov EE, Popkova TV, Starodubova AV, Orekhov AN. Immunity in atherosclerosis: focusing on T and B cells. Int J Mol Sci 2021;22:8379.
101. Vakhtangadze T, Singh Tak R, Singh U, Baig MS, Bezsonov E. Gender differences in atherosclerotic vascular disease: from lipids to clinical outcomes. Front Cardiovasc Med 2021;8:707889.
102. Kuro OM. Phosphate as a pathogen of arteriosclerosis and aging. J Atheroscler Thromb 2021;28:203-13.
103. Ellam TJ, Chico TJA. Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis 2012;220:310-8.
104. McCarthy L, Downey M. The emerging landscape of eukaryotic polyphosphatases. FEBS Lett 2023;597:1447-61.
105. Kalebina TS, Egorov SN, Arbatskii NP, Bezsonov EE, Gorkovskii AA, Kulaev IS. The role of high-molecular-weight polyphosphates in activation of glucan transferase Bgl2p from Saccharomyces cerevisiae cell wall. Dokl Biochem Biophys 2008;420:142-5.
106. Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012;119:5972-9.
107. Peng W, Cai G, Xia Y, et al. Mitochondrial dysfunction in atherosclerosis. DNA Cell Biol 2019;38:597-606.
108. Durham AL, Speer MY, Scatena M, Giachelli CM, Shanahan CM. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovasc Res 2018;114:590-600.
109. Sazonova MA, Sinyov VV, Barinova VA, et al. Association of mitochondrial mutations with the age of patients having atherosclerotic lesions. Exp Mol Pathol 2015;99:717-9.
110. Calabrese C, Pyle A, Griffin H, et al. Heteroplasmic mitochondrial DNA variants in cardiovascular diseases. PLoS Genet 2022;18:e1010068.
111. Hefti E, Blanco JG. Mitochondrial DNA heteroplasmy in cardiac tissue from individuals with and without coronary artery disease. Mitochondrial DNA A DNA Mapp Seq Anal 2018;29:587-93.
112. Röcken C, Tautenhahn J, Bühling F, et al. Prevalence and pathology of amyloid in atherosclerotic arteries. Arterioscler Thromb Vasc Biol 2006;26:676-7.
113. Wickner RB, Bezsonov EE, Son M, Ducatez M, DeWilde M, Edskes HK. Anti-prion systems in yeast and inositol polyphosphates. Biochemistry 2018;57:1285-92.
114. Bezsonov EE, Groenning M, Galzitskaya OV, et al. Amyloidogenic peptides of yeast cell wall glucantransferase Bgl2p as a model for the investigation of its pH-dependent fibril formation. Prion 2013;7:175-84.
115. Wickner RB, Edskes HK, Bateman DA, et al. Yeast prions: proteins templating conformation and an anti-prion system. PLoS Pathog 2015;11:e1004584.
117. Wu NN, Zhang Y, Ren J. Mitophagy, mitochondrial dynamics, and homeostasis in cardiovascular aging. Oxid Med Cell Longev 2019;2019:1-15.
118. Wang JC, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 2012;111:245-59.
119. Martinet W, Knaapen MWM, De Meyer GRY, Herman AG, Kockx MM. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 2002;106:927-32.
120. Breitschopf K, Zeiher AM, Dimmeler S. Pro-atherogenic factors induce telomerase inactivation in endothelial cells through an Akt-dependent mechanism. FEBS Lett 2001;493:21-5.
121. Sahin E, Colla S, Liesa M, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011;470:359-65.
122. Gusev E, Sarapultsev A. Atherosclerosis and inflammation: insights from the theory of general pathological processes. Int J Mol Sci 2023;24:7910.
123. Koushki K, Keshavarz Shahbaz S, Keshavarz M, Bezsonov EE, Sathyapalan T, Sahebkar A. Gold nanoparticles: multifaceted roles in the management of autoimmune disorders. Biomolecules 2021;11:1289.
124. Orekhov AN, Poznyak AV, Sobenin IA, Nikifirov NN, Ivanova EA. Mitochondrion as a selective target for the treatment of atherosclerosis: role of mitochondrial DNA mutations and defective mitophagy in the pathogenesis of atherosclerosis and chronic inflammation. Curr Neuropharmacol 2020;18:1064-75.
125. Sobenin IA, Sazonova MA, Postnov AY, Bobryshev YV, Orekhov AN. Mitochondrial mutations are associated with atherosclerotic lesions in the human aorta. Clin Dev Immunol 2012;2012:832464.
126. Zhunina OA, Yabbarov NG, Grechko AV, et al. The role of mitochondrial dysfunction in vascular disease, tumorigenesis, and diabetes. Front Mol Biosci 2021;8:671908.
127. Volobueva A, Grechko A, Yet SF, Sobenin I, Orekhov A. Changes in mitochondrial genome associated with predisposition to atherosclerosis and related disease. Biomolecules 2019;9:377.
128. Yu E, Calvert PA, Mercer JR, et al. Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans. Circulation 2013;128:702-12.
129. Sobenin IA, Zhelankin AV, Khasanova ZB, et al. Heteroplasmic variants of mitochondrial DNA in Atherosclerotic lesions of human aortic intima. Biomolecules 2019;9:455.
130. Freigang S, Hörkkö S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998;18:1972-82.
131. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011;469:221-5.
132. Tall AR, Bornfeldt KE. Inflammasomes and atherosclerosis: a mixed picture. Circ Res 2023;132:1505-20.
133. Bulté D, Rigamonti C, Romano A, Mortellaro A. Inflammasomes: mechanisms of action and involvement in human diseases. Cells 2023;12:1766.
134. Shahbaz S, Koushki K, Ayati SH, Bland AR, Bezsonov EE, Sahebkar A. Inflammasomes and colorectal cancer. Cells 2021;10:2172.
135. Coppi L, Ligorio S, Mitro N, Caruso D, De Fabiani E, Crestani M. PGC1s and beyond: disentangling the complex regulation of mitochondrial and cellular metabolism. Int J Mol Sci 2021;22:6913.
136. Sazonova MA, Sinyov VV, Ryzhkova AI, et al. Creation of cybrid cultures containing mtDNA mutations m.12315G>A and
137. Wang X, Xu M, Frank JA, Ke ZJ, Luo J. Thiamine deficiency induces endoplasmic reticulum stress and oxidative stress in human neurons derived from induced pluripotent stem cells. Toxicol Appl Pharmacol 2017;320:26-31.
138. Colombo B, Saraceno L, Comi G. Riboflavin and migraine: the bridge over troubled mitochondria. Neurol Sci 2014;35 Suppl 1:141-4.
139. Song SB, Jang SY, Kang HT, et al. Modulation of mitochondrial membrane potential and ROS generation by nicotinamide in a manner independent of SIRT1 and mitophagy. Mol Cells 2017;40:503-14.
140. Kang HT, Hwang ES. Nicotinamide enhances mitochondria quality through autophagy activation in human cells. Aging Cell 2009;8:426-38.
141. Gao X, Lee K, Reid MA, et al. Serine availability influences mitochondrial dynamics and function through lipid metabolism. Cell Rep 2018;22:3507-20.
142. Onodera R, Motoyama K, Tanaka N, et al. Involvement of autophagy in antitumor activity of folate-appended methyl-β-cyclodextrin. Sci Rep 2014;4:4417.
144. McCarty MF, Assanga SBI. Ferulic acid may target MyD88-mediated pro-inflammatory signaling - implications for the health protection afforded by whole grains, anthocyanins, and coffee. Med Hypotheses 2018;118:114-20.
145. Bumrungpert A, Lilitchan S, Tuntipopipat S, Tirawanchai N, Komindr S. Ferulic acid supplementation improves lipid profiles, oxidative stress, and inflammatory status in hyperlipidemic subjects: a randomized, double-blind, placebo-controlled clinical trial. Nutrients 2018;10:713.
146. Sgarbossa A, Giacomazza D, di Carlo M. Ferulic acid: a hope for Alzheimer’s disease therapy from plants. Nutrients 2015;7:5764-82.
147. Neto-Neves EM, da Silva Maia Bezerra Filho C, Dejani NN, de Sousa DP. Ferulic acid and cardiovascular health: therapeutic and preventive potential. Mini Rev Med Chem 2021;21:1625-37.
148. Nankar R, Prabhakar PK, Doble M. Hybrid drug combination: combination of ferulic acid and metformin as anti-diabetic therapy. Phytomedicine 2017;37:10-3.
149. Sultana R. Ferulic acid ethyl ester as a potential therapy in neurodegenerative disorders. Biochim Biophys Acta 2012;1822:748-52.
150. Gupta A, Singh AK, Loka M, Pandey AK, Bishayee A. Chapter eight - ferulic acid-mediated modulation of apoptotic signaling pathways in cancer. In: Advances in protein chemistry and structural biology. 2021. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1876162320300912 [Last accessed on 5 Dec 2023].
151. Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008;57:1414-8.
152. Cicero AFG, Baggioni A. Berberine and its role in chronic disease. In: Gupta SC, Prasad S, Aggarwal BB, editors. Anti-inflammatory nutraceuticals and chronic diseases. Cham: Springer International Publishing; 2016. pp. 27-45. Available from: http://link.springer.com/10.1007/978-3-319-41334-1_2 [Last accessed on 5 Dec 2023].
153. Kyung S, Lim JW, Kim H. α-lipoic acid inhibits IL-8 expression by activating Nrf2 signaling in helicobacter pylori-infected gastric epithelial cells. Nutrients 2019;11:2524.
154. Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother 2014;15:2721-31.
155. Novotny L, Rauko P, Cojocel C. alpha-Lipoic acid: the potential for use in cancer therapy. Neoplasma 2008;55:81-6.
156. Barut EN, Engin S, Saygın İ, Kaya-Yasar Y, Arici S, Sezen SF. Alpha-lipoic acid: a promising adjuvant for nonsteroidal anti-inflammatory drugs therapy with improved efficacy and gastroprotection. Drug Dev Res 2021;82:844-51.
157. Tóth F, Cseh EK, Vécsei L. Natural molecules and neuroprotection: kynurenic acid, pantethine and α-lipoic acid. Int J Mol Sci 2021;22:403.
158. Krestinina O, Baburina Y, Krestinin R, Odinokova I, Fadeeva I, Sotnikova L. Astaxanthin prevents mitochondrial impairment induced by isoproterenol in isolated rat heart mitochondria. Antioxidants 2020;9:262.
159. Li J, Guo C, Wu J. Astaxanthin in liver health and disease: a potential therapeutic agent. Drug Des Devel Ther 2020;14:2275-85.
160. Krestinina O, Baburina Y, Krestinin R. Mitochondrion as a target of astaxanthin therapy in heart failure. Int J Mol Sci 2021;22:7964.
161. Giannaccare G, Pellegrini M, Senni C, Bernabei F, Scorcia V, Cicero AFG. Clinical applications of astaxanthin in the treatment of ocular diseases: emerging insights. Mar Drugs 2020;18:239.
162. McCarty MF, O’Keefe JH, DiNicolantonio JJ. Glucosamine for the treatment of osteoarthritis: the time has come for higher-dose trials. J Diet Suppl 2019;16:179-92.
163. Feng KM, Chien WC, Chen JT, et al. The impact of glucosamine on age-related macular degeneration in patients: a nationwide, population-based cohort study. PLoS ONE 2021;16:e0251925.
164. Yu L, Sun Y, Cheng L, et al. Melatonin receptor-mediated protection against myocardial ischemia/reperfusion injury: role of SIRT1. J Pineal Res 2014;57:228-38.
165. Fang J, Yan Y, Teng X, et al. Melatonin prevents senescence of canine adipose-derived mesenchymal stem cells through activating NRF2 and inhibiting ER stress. Aging 2018;10:2954-72.
166. Chitimus DM, Popescu MR, Voiculescu SE, et al. Melatonin’s impact on antioxidative and anti-inflammatory reprogramming in homeostasis and disease. Biomolecules 2020;10:1211.
167. Talib WH, Alsayed AR, Abuawad A, Daoud S, Mahmod AI. Melatonin in cancer treatment: current knowledge and future opportunities. Molecules 2021;26:2506.
168. Lalanne S, Fougerou-Leurent C, Anderson GM, et al. Melatonin: from pharmacokinetics to clinical use in autism spectrum disorder. Int J Mol Sci 2021;22:1490.
169. Chokchaiwong S, Kuo YT, Lin SH, et al. Coenzyme Q10 serves to couple mitochondrial oxidative phosphorylation and fatty acid β-oxidation, and attenuates NLRP3 inflammasome activation. Free Radic Res 2018;52:1445-55.
170. Wang D, Yan X, Xia M, et al. Coenzyme Q10 promotes macrophage cholesterol efflux by regulation of the activator protein-1/
171. Mercer JR, Yu E, Figg N, et al. The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in
172. Xiao L, Xu X, Zhang F, et al. The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1. Redox Biol 2017;11:297-311.
173. Mahmoudi K, Garvey KL, Bouras A, et al. 5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas. J Neurooncol 2019;141:595-607.
174. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014;10:143-56.
175. Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006;47:1183-8.
176. LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev 2021;42:77-96.
177. La Fountaine MF, Cirnigliaro CM, Hobson JC, et al. Fenofibrate therapy to lower serum triglyceride concentrations in persons with spinal cord injury: a preliminary analysis of its safety profile. J Spinal Cord Med 2020;43:704-9.
178. Pettersen JC, Pruimboom-Brees I, Francone OL, et al. The PPARα agonists fenofibrate and CP-778875 cause increased β-oxidation, leading to oxidative injury in skeletal and cardiac muscle in the rat. Toxicol Pathol 2012;40:435-47.
179. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-α/PGC-1α gene regulatory pathway. Circulation 2007;115:909-17.
180. El-hattab AW, Craigen WJ, Scaglia F. Mitochondrial DNA maintenance defects. BBA Mol Basis Dis 2017;1863:1539-55.
181. De Marco V, Noronha KSM, Casado TC, et al. Therapy of canine hyperlipidemia with bezafibrate. J Vet Intern Med 2017;31:717-22.
182. Bonnefont JP, Bastin J, Laforêt P, et al. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther 2010;88:101-8.
183. Ren B, Kwah MXY, Liu C, et al. Resveratrol for cancer therapy: challenges and future perspectives. Cancer Lett 2021;515:63-72.
184. Huang DD, Shi G, Jiang Y, Yao C, Zhu C. A review on the potential of Resveratrol in prevention and therapy of diabetes and diabetic complications. Biomed Pharmacother 2020;125:109767.
185. Breuss JM, Atanasov AG, Uhrin P. Resveratrol and its effects on the vascular system. Int J Mol Sci 2019;20:1523.
186. Komen JC, Thorburn DR. Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models. Br J Pharmacol 2014;171:1818-36.
187. Fu CY, Zhong CR, Yang YT, et al. Sirt1 activator SRT2104 protects against oxygen-glucose deprivation/reoxygenation-induced injury via regulating microglia polarization by modulating Sirt1/NF-κB pathway. Brain Res 2021;1753:147236.
188. Libri V, Brown AP, Gambarota G, et al. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One 2012;7:e51395.
189. Madhavi YV, Gaikwad N, Yerra VG, Kalvala AK, Nanduri S, Kumar A. Targeting AMPK in diabetes and diabetic complications: energy homeostasis, autophagy and mitochondrial health. Curr Med Chem 2019;26:5207-29.
190. Dombi E, Mortiboys H, Poulton J. Modulating mitophagy in mitochondrial disease. Curr Med Chem 2019;25:5597-612.
191. Golubitzky A, Dan P, Weissman S, Link G, Wikstrom JD, Saada A. Screening for active small molecules in mitochondrial complex I deficient patient’s fibroblasts, reveals AICAR as the most beneficial compound. PLoS One 2011;6:e26883.
192. Moreno-Ulloa A, Cid A, Rubio-Gayosso I, Ceballos G, Villarreal F, Ramirez-Sanchez I. Effects of (-)-epicatechin and derivatives on nitric oxide mediated induction of mitochondrial proteins. Bioorg Med Chem Lett 2013;23:4441-6.
193. Keller A, Hull SE, Elajaili H, et al. (-)-Epicatechin modulates mitochondrial redox in vascular cell models of oxidative stress. Oxid Med Cell Longev 2020;2020:6392629.
194. Chen Q, Wang T, Li J, et al. Effects of natural products on fructose-induced nonalcoholic fatty liver disease (NAFLD). Nutrients 2017;9:96.
195. Chun JH, Henckel MM, Knaub LA, et al. (-)-Epicatechin improves vasoreactivity and mitochondrial respiration in thermoneutral-housed wistar rat vasculature. Nutrients 2022;14:1097.
196. Tanabe K, Tamura Y, Lanaspa MA, et al. Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy. Am J Physiol Renal Physiol 2012;303:F1264-74.
197. Chen Q, Li Q, Liang Y, et al. Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulation. Acta Pharm Sin B 2022;12:907-23.
198. Rai PK, Russell OM, Lightowlers RN, Turnbull DM. Potential compounds for the treatment of mitochondrial disease. Br Med Bull 2015;116:5-18.
199. Sun X, Xie Z, Hu B, et al. The Nrf2 activator RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling. Redox Biol 2020;28:101309.
200. Zhang L, Zhou Q, Zhou CL. RTA-408 protects against propofol-induced cognitive impairment in neonatal mice via the activation of Nrf2 and the inhibition of NF-κB p65 nuclear translocation. Brain Behav 2021;11:e01918.
201. Rabbani PS, Ellison T, Waqas B, et al. Targeted Nrf2 activation therapy with RTA 408 enhances regenerative capacity of diabetic wounds. Diabetes Res Clin Pract 2018;139:11-23.
203. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res 2017;120:229-43.
204. Babelova A, Sedding DG, Brandes RP. Anti-atherosclerotic mechanisms of statin therapy. Curr Opin Pharmacol 2013;13:260-4.
205. Kong F, Ye B, Lin L, Cai X, Huang W, Huang Z. Atorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/
206. Apostolopoulou M, Corsini A, Roden M. The role of mitochondria in statin-induced myopathy. Eur J Clin Invest 2015;45:745-54.
207. Yang S, Wu GL, Li N, et al. A mitochondria-targeted molecular phototheranostic platform for NIR-II imaging-guided synergistic photothermal/photodynamic/immune therapy. J Nanobiotechnol 2022;20:475.
208. Wormald RPL, Evans JR, Smeeth LL, Henshaw KS. Photodynamic therapy for neovascular age-related macular degeneration. Chichester, UK: John Wiley & Sons, Ltd; 2003. p. CD002030. Available from: https://doi.wiley.com/10.1002/14651858.CD002030 [Last accessed on 5 Dec 2023].
209. Wen X, Li Y, Hamblin MR. Photodynamic therapy in dermatology beyond non-melanoma cancer: an update. Photodiagnosis Photodyn Ther 2017;19:140-52.
210. Zhang Y, Zhou Q, Bu Y, et al. Real-time imaging mitochondrial viscosity dynamic during mitophagy mediated by photodynamic therapy. Anal Chim Acta 2021;1178:338847.
211. Agostinis P, Vantieghem A, Merlevede W, de Witte PAM. Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol 2002;34:221-41.
212. Galanou MC, Theodossiou TA, Tsiourvas D, Sideratou Z, Paleos CM. Interactive transport, subcellular relocation and enhanced phototoxicity of hypericin encapsulated in guanidinylated liposomes via molecular recognition. Photochem Photobiol 2008;84:1073-83.
213. Dong X, Zeng Y, Zhang Z, et al. Hypericin-mediated photodynamic therapy for the treatment of cancer: a review. J Pharm Pharmacol 2021;73:425-36.
214. Courrol LC, de Oliveira Silva FR, Masilamani V. SARS-CoV-2, hemoglobin and protoporphyrin IX: interactions and perspectives. Photodiagnosis Photodyn Ther 2021;34:102324.
215. Gammage PA, Viscomi C, Simard ML, et al. Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo. Nat Med 2018;24:1691-5.
216. El-Hattab AW, Zarante AM, Almannai M, Scaglia F. Therapies for mitochondrial diseases and current clinical trials. Mol Genet Metab 2017;122:1-9.
217. Wang J, El-Hattab AW, Wong LJC. TK2-related mitochondrial DNA maintenance defect, myopathic form. Seattle: University of Washington; 1993. Available from: http://www.ncbi.nlm.nih.gov/books/NBK114628/ [Last accessed on 5 Dec 2023].
